Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer

Abstract

IntroductionThis study was designed to investigate the combined influence of ATM and Ki67 on clinical outcome in early stage hormone receptor positive breast cancer (ES-HPBC), particularly in patients with smaller tumors (< 4 cm) and fewer than four positive lymph nodes.Methods532 formalin-fixed paraffin-embedded specimens of resected primary breast tumors were used to construct a tissue microarray. Samples from 297 patients were suitable for final statistical analysis. We detected ATM and Ki67 proteins using fluorescence and brightfield immunohistochemistry respectively, and quantified their expression with digital image analysis. Data on expression levels were subsequently correlated with clinical outcome.ResultsRemarkably, ATM expression was useful to stratify the low Ki67 group into subgroups with better or poorer prognosis. Specifically, in the low Ki67 subgroup defined as having smaller tumors and no positive nodes, patients with high ATM expression showed better outcome than those with low ATM, with estimated survival rates of 96% and 89% respectively at 15 years follow up (p = 0.04). Similarly, low-Ki67 patients with smaller tumors, 1-3 positive nodes and high ATM also had significantly better outcomes than their low ATM counterparts, with estimated survival rates of 88% and 46% respectively (p = 0.03) at 15 years follow up. Multivariable analysis indicated that the combination of high ATM and low Ki67 is prognostic of improved survival, independent of tumor size, grade, and lymph node status (p = 0.02).ConclusionsThese data suggest that the prognostic value of Ki67 can be improved by analyzing ATM expression in ES-HPBC.

Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC‑8 stratification

“…Feng et al (52) reported that elevated Ki67 expression is associated with poorer prognosis in breast cancer. Shin et al (53) pointed out that high Ki67 reflects poor prognosis in CRC.…”

P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients

“…Ki-67 associates with cell cycle progress and the short half-life confer it an effective biomarker for assessing growth fraction of tumor cells. Ki-67 is one of the most widely used immunohistochemistry (IHC) proliferation antigen and has been confirmed as an independent predictive and prognostic factor in breast cancer [ 15 , 16 ]. Ki-67 is an important parameter in sub-classifying luminal tumors into a good prognosis luminal A subtype and a worse prognosis luminal B subtype [ 17 ].…”

Prolyl hydroxylase domain protein 3 and asparaginyl hydroxylase factor inhibiting HIF-1 levels are predictive of tumoral behavior and prognosis in hepatocellular carcinoma

“…The percentage of Ki-67-positive nuclei to the total number of nuclei was used as the labeling index [75]. …”

“…Five representative areas of each section were chosen to count the immunoreactive cells, and at least 200 cells from each area were evaluated (×400). The percentage of Ki-67-positive nuclei to the total number of nuclei was used as the labeling index [ 75 ].…”